Replies to post #131064 on Biotech Values

[oc631]

It’s getting easier to catch up as the duration of treatment in clinical trials continues to shrink.

But the challenges remain. Safety, tolerability, potency/dosing, efficacy, and resistance profile. It's interesting how many HCV developers are working on purine nukes while the most successful nucleotide to date (PSI-7977) is pyrimidine based. Do you know of any other developers working on a pyrimidine?

[biomaven0]

It’s getting easier to catch up as the duration of treatment in clinical trials continues to shrink.

For a program not in the clinic yet, we'd still be looking at something like 2016 at the earliest for approval, right?

Peter